BR112013022279A2 - proteína de fusão induzível anti-angiogênico e o seu uso - Google Patents

proteína de fusão induzível anti-angiogênico e o seu uso

Info

Publication number
BR112013022279A2
BR112013022279A2 BR112013022279A BR112013022279A BR112013022279A2 BR 112013022279 A2 BR112013022279 A2 BR 112013022279A2 BR 112013022279 A BR112013022279 A BR 112013022279A BR 112013022279 A BR112013022279 A BR 112013022279A BR 112013022279 A2 BR112013022279 A2 BR 112013022279A2
Authority
BR
Brazil
Prior art keywords
angiogenic
fusion protein
inducible fusion
inducible
protein
Prior art date
Application number
BR112013022279A
Other languages
English (en)
Other versions
BR112013022279B1 (pt
Inventor
Dong Li
Jianmin Fang
Original Assignee
Yantai Rongchang Biotechnilogies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Rongchang Biotechnilogies Co Ltd filed Critical Yantai Rongchang Biotechnilogies Co Ltd
Publication of BR112013022279A2 publication Critical patent/BR112013022279A2/pt
Publication of BR112013022279B1 publication Critical patent/BR112013022279B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013022279-4A 2011-05-20 2012-05-18 Proteína de fusão para antagonizar fatores induzíveis de angionêse e utilizações da mesma BR112013022279B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110131029.X 2011-05-20
CN201110131029A CN102219859B (zh) 2011-05-20 2011-05-20 拮抗血管新生诱导因子的融合蛋白及其用途
PCT/CN2012/075700 WO2012159548A1 (zh) 2011-05-20 2012-05-18 拮抗血管新生诱导因子的融合蛋白及其用途

Publications (2)

Publication Number Publication Date
BR112013022279A2 true BR112013022279A2 (pt) 2016-12-06
BR112013022279B1 BR112013022279B1 (pt) 2020-12-15

Family

ID=44776584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022279-4A BR112013022279B1 (pt) 2011-05-20 2012-05-18 Proteína de fusão para antagonizar fatores induzíveis de angionêse e utilizações da mesma

Country Status (10)

Country Link
US (1) US9522949B2 (pt)
EP (1) EP2711377B1 (pt)
JP (2) JP2014513940A (pt)
KR (2) KR101682496B1 (pt)
CN (1) CN102219859B (pt)
AU (1) AU2012261410B2 (pt)
BR (1) BR112013022279B1 (pt)
CA (1) CA2831161C (pt)
RU (1) RU2560589C2 (pt)
WO (1) WO2012159548A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
EP2785744B1 (en) * 2011-12-01 2017-10-04 AP Biosciences, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
LT2968461T (lt) * 2013-03-13 2022-12-27 Genzyme Corporation Sulieti baltymai, apimantys pdgf ir vegf surišančius fragmentus, ir jų panaudojimo būdai
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
WO2015109898A1 (zh) * 2014-01-24 2015-07-30 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
CN105983093A (zh) * 2015-02-11 2016-10-05 烟台荣昌生物工程有限公司 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用
CN106084062B (zh) * 2015-04-28 2021-04-02 荣昌生物制药（烟台）有限公司 桥连的双特异性融合蛋白
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
CN110248672A (zh) * 2017-02-06 2019-09-17 中央研究院 重组蛋白及其用途
WO2019126329A1 (en) * 2017-12-19 2019-06-27 Akouos Llc Aav-mediated delivery of therapeutic antibodies to the inner ear
CA3092320C (en) * 2018-12-07 2023-09-19 Remegen Co., Ltd. Bifunctional angiogenesis inhibitor and use thereof
CN112206309A (zh) * 2019-07-11 2021-01-12 滨州医学院 双靶点血管抑制剂在制备预防或治疗纤维化药物中的用途
CN110423281B (zh) * 2019-07-31 2021-04-30 成都金唯科生物科技有限公司 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
CN110627905B (zh) * 2019-09-18 2021-04-27 中国医学科学院肿瘤医院 靶向vegf与egfr的双功能融合蛋白及其应用
CN113046390B (zh) * 2020-03-09 2024-01-09 百奥赛图江苏基因生物技术有限公司 Csf1r基因人源化的非人动物及其构建方法和应用
CN115850441B (zh) * 2022-11-22 2023-10-24 无锡市人民医院 一种特异性靶向降解egfr及其突变体的重组蛋白、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
EP1745073A2 (en) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
DE602006010874D1 (de) * 2005-07-22 2010-01-14 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
CA2655205A1 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
RU2418003C2 (ru) * 2006-11-10 2011-05-10 КовЭкс Текнолоджиз Айэлэнд Лимитед Антиангиогенные соединения
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
EP2326345B1 (en) 2008-08-22 2015-01-14 The Trustees of Columbia University in the City of New York Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
CN101838329A (zh) 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途

Also Published As

Publication number Publication date
EP2711377B1 (en) 2017-10-18
EP2711377A1 (en) 2014-03-26
KR20130125809A (ko) 2013-11-19
RU2560589C2 (ru) 2015-08-20
WO2012159548A1 (zh) 2012-11-29
BR112013022279B1 (pt) 2020-12-15
CA2831161C (en) 2017-09-12
JP2014513940A (ja) 2014-06-19
JP2016106128A (ja) 2016-06-16
JP6328164B2 (ja) 2018-05-23
RU2013140472A (ru) 2015-03-10
AU2012261410A1 (en) 2013-10-17
KR101682496B1 (ko) 2016-12-12
AU2012261410B2 (en) 2016-03-03
US9522949B2 (en) 2016-12-20
EP2711377A4 (en) 2014-12-31
KR20160011240A (ko) 2016-01-29
CA2831161A1 (en) 2012-11-29
CN102219859A (zh) 2011-10-19
US20130190235A1 (en) 2013-07-25
CN102219859B (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
BR112013022279A2 (pt) proteína de fusão induzível anti-angiogênico e o seu uso
CO6870005A2 (es) Composición anti-cgrp y uso de las mismas
BR112015003838A2 (pt) formulações de anticorpo e proteína
BR112014000055A2 (pt) polipeptídeos de fusão de relaxina e usos dos mesmos
CO7020851A2 (es) Proteínas y péptidos modificados
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
BR112013022285A2 (pt) proteína de fusão de fgfr-fc e o seu uso
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
IL229753A0 (en) Proteins that release relaxin and their use
BR112014024373A2 (pt) anticorpos regulados por protease
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
BR112014004936A2 (pt) polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
HRP20190434T1 (hr) Fuzijski protein
SMT201500203B (it) Proteina di fusione anticancro
DOS2012000099S (es) Botella
BR112013033919A2 (pt) combinações e seus usos
CO6900119A2 (es) Uso de proteína cristalina insecticida dig3 en combinación con cry1ab
DK2610053T3 (da) Sandwichkernemateriale
EP2969009A4 (en) MODIFIED FC FUSION PROTEINS
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
DK2869845T3 (da) Dimert protein med tredobbelte mutationer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2012, OBSERVADAS AS CONDICOES LEGAIS.